Your browser doesn't support javascript.
loading
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; Wang, J; Wang, Y; Lee, S-H; Melosky, B; Shih, J-Y; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, A B; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, J-L; Salinas, J; Tomasini, P; Gentzler, R D; William, W N; Reckamp, K L; Takahashi, T; Ganguly, S; Kowalski, D M; Bearz, A; MacKean, M; Barala, P; Bourla, A B; Girvin, A; Greger, J; Millington, D; Withelder, M; Xie, J; Sun, T; Shah, S; Diorio, B; Knoblauch, R E; Bauml, J M; Campelo, R G; Cho, B C.
Afiliação
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: antonio.passaro@ieo.it.
  • Wang J; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Wang Y; Department of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Lee SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Melosky B; British Columbia Cancer Agency, Vancouver, Canada.
  • Shih JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Wang J; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Azuma K; Kurume University School of Medicine, Kurume, Japan.
  • Juan-Vidal O; Hospital Universitari i Politécnic La Fe, Valencia, Spain.
  • Cobo M; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.
  • Felip E; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Girard N; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, France.
  • Cortot AB; University of Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Califano R; Department of Medical Oncology, Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, UK.
  • Cappuzzo F; IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Owen S; Department of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Popat S; Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK.
  • Tan JL; Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Salinas J; Centro de Especialidades Medicas Ambulatorias e Investigación Clínica, Córdoba, Argentina.
  • Tomasini P; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.
  • Gentzler RD; Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA.
  • William WN; Centro Oncológico BP, Beneficência Portuguesa de São Paulo, and Grupo Oncoclínicas, São Paulo, Brazil.
  • Reckamp KL; Cedars-Sinai Medical Center, Los Angeles, USA.
  • Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Ganguly S; Tata Medical Center, Kolkata, India.
  • Kowalski DM; Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Bearz A; Medical Oncology, Centro di Riferimento Oncologico-CRO, Aviano, Italy.
  • MacKean M; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
  • Barala P; Janssen Research & Development, Spring House, PA, USA.
  • Bourla AB; Janssen Research & Development, Raritan, NJ, USA.
  • Girvin A; Janssen Research & Development, Spring House, PA, USA.
  • Greger J; Janssen Research & Development, Spring House, PA, USA.
  • Millington D; Janssen Research & Development, San Diego, CA, USA.
  • Withelder M; Janssen Research & Development, Spring House, PA, USA.
  • Xie J; Janssen Research & Development, Raritan, NJ, USA.
  • Sun T; Janssen Research & Development, Raritan, NJ, USA.
  • Shah S; Janssen Research & Development, Spring House, PA, USA.
  • Diorio B; Janssen Research & Development, Raritan, NJ, USA.
  • Knoblauch RE; Janssen Research & Development, Spring House, PA, USA.
  • Bauml JM; Janssen Research & Development, Spring House, PA, USA.
  • Campelo RG; University Hospital A Coruña, A Coruña, Spain.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ann Oncol ; 35(1): 77-90, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37879444
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Acrilamidas / Morfolinas / Anticorpos Biespecíficos / Carcinoma Pulmonar de Células não Pequenas / Indóis / Compostos de Anilina / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Acrilamidas / Morfolinas / Anticorpos Biespecíficos / Carcinoma Pulmonar de Células não Pequenas / Indóis / Compostos de Anilina / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article